Pentair Plc (PNR) Share Value Declined While Trian Fund Management LP Upped Its Stake; Ra Capital Management Has Trimmed Its Position in Achillion Pharmaceuticals (ACHN) by $26.09 Million as Stock Price Rose

April 23, 2018 - By Richard Conner

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Logo

Peter Kolchinsky decreased its stake in Achillion Pharmaceuticals Inc (ACHN) by 95.7% based on its latest 2017Q4 regulatory filing with the SEC. Ra Capital Management Llc sold 13.05M shares as the company’s stock rose 28.04% while stock markets declined. The hedge fund run by Peter Kolchinsky held 585,890 shares of the health care company at the end of 2017Q4, valued at $1.69M, down from 13.63 million at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Achillion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $507.45 million market cap company. The stock increased 0.82% or $0.03 during the last trading session, reaching $3.68. About 162,877 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since April 23, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.

Nelson Peltz increased its stake in Pentair Plc (PNR) by 1.39% based on its latest 2017Q4 regulatory filing with the SEC. Trian Fund Management Lp bought 210,876 shares as the company’s stock declined 2.08% with the market. The hedge fund run by Nelson Peltz held 15.41M shares of the industrial machinery and components company at the end of 2017Q4, valued at $1.09B, up from 15.20 million at the end of the previous reported quarter. Trian Fund Management Lp who had been investing in Pentair Plc for a number of months, seems to be bullish on the $12.51B market cap company. The stock decreased 0.41% or $0.29 during the last trading session, reaching $70.16. About 332,302 shares traded. Pentair plc (NYSE:PNR) has risen 11.82% since April 23, 2017 and is uptrending. It has outperformed by 0.27% the S&P500.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on May, 3. They expect $-0.14 EPS, up 6.67% or $0.01 from last year’s $-0.15 per share. After $-0.17 actual EPS reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -17.65% EPS growth.

Investors sentiment increased to 2.08 in Q4 2017. Its up 1.12, from 0.96 in 2017Q3. It increased, as 10 investors sold ACHN shares while 28 reduced holdings. 34 funds opened positions while 45 raised stakes. 110.36 million shares or 4.96% more from 105.14 million shares in 2017Q3 were reported. State Street Corp holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 5.71M shares. State Common Retirement Fund owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 118,300 shares. Ing Groep Nv has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). 479,363 were accumulated by Qs Invsts Ltd Liability Company. Integral Derivatives Ltd invested in 0% or 15,368 shares. Arrowmark Colorado holds 935,987 shares. Cubist Systematic Strategies reported 17,692 shares. Sabby Management invested in 16,705 shares or 0% of the stock. Raymond James And Associates accumulated 68,450 shares. State Board Of Administration Of Florida Retirement System holds 0% or 75,246 shares. Moreover, Jpmorgan Chase And Comm has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Ecor1 Capital Limited Liability Corporation owns 1.84 million shares. Pacad Inv reported 43,096 shares. Metropolitan Life Company New York stated it has 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Spark Invest Mgmt Llc reported 701,000 shares.

Among 11 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Achillion Pharma had 27 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Hold” rating by FBR Capital on Friday, February 23. Robert W. Baird maintained the stock with “Hold” rating in Monday, October 23 report. The firm has “Market Perform” rating by Leerink Swann given on Friday, January 29. The firm earned “Hold” rating on Wednesday, September 9 by Jefferies. Chardan Capital Markets maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Wednesday, August 9 with “Hold” rating. The firm has “Buy” rating given on Tuesday, September 8 by UBS. The stock has “Sell” rating by Chardan Capital Markets on Thursday, July 14. The stock has “Outperform” rating by Robert W. Baird on Friday, February 26. The company was initiated on Friday, September 23 by Wedbush. The company was maintained on Wednesday, August 9 by Maxim Group.

Ra Capital Management Llc, which manages about $1.48 billion and $1.20B US Long portfolio, upped its stake in Zogenix Inc by 153,000 shares to 1.15M shares, valued at $45.87M in 2017Q4, according to the filing.

Among 24 analysts covering Pentair Inc. (NYSE:PNR), 7 have Buy rating, 4 Sell and 13 Hold. Therefore 29% are positive. Pentair Inc. had 86 analyst reports since July 22, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Outperform” rating and $60 target in Friday, December 18 report. The stock of Pentair plc (NYSE:PNR) earned “Hold” rating by Robert W. Baird on Tuesday, October 24. Cowen & Co maintained Pentair plc (NYSE:PNR) rating on Tuesday, May 30. Cowen & Co has “Sell” rating and $5900 target. The rating was maintained by Morgan Stanley on Monday, October 2 with “Overweight”. The rating was maintained by BMO Capital Markets on Wednesday, August 2 with “Hold”. As per Monday, October 16, the company rating was maintained by BMO Capital Markets. The stock has “Hold” rating by Robert W. Baird on Thursday, April 19. The stock has “Hold” rating by Oppenheimer on Wednesday, August 16. KeyBanc Capital Markets maintained the shares of PNR in report on Tuesday, October 24 with “Buy” rating. Susquehanna maintained Pentair plc (NYSE:PNR) rating on Wednesday, April 27. Susquehanna has “Positive” rating and $67 target.

Trian Fund Management Lp, which manages about $8.60B and $11.82 billion US Long portfolio, decreased its stake in Bank New York Mellon Corp. (NYSE:BK) by 6.60 million shares to 15.78M shares, valued at $849.72M in 2017Q4, according to the filing.

Investors sentiment increased to 1.18 in Q4 2017. Its up 0.14, from 1.04 in 2017Q3. It is positive, as 31 investors sold PNR shares while 139 reduced holdings. 66 funds opened positions while 134 raised stakes. 154.07 million shares or 1.95% more from 151.12 million shares in 2017Q3 were reported. Hsbc Public Ltd Com holds 0.01% in Pentair plc (NYSE:PNR) or 120,122 shares. Moreover, Oregon Pub Employees Retirement Fund has 0.02% invested in Pentair plc (NYSE:PNR). Hudock Grp Ltd Co invested in 8 shares. Employees Retirement Of Texas holds 0.01% or 9,000 shares. 13D Mngmt Lc holds 124,119 shares. Parametric Portfolio Assocs Ltd Liability Co, Washington-based fund reported 317,444 shares. Moreover, Bp Public Limited Com has 0.06% invested in Pentair plc (NYSE:PNR). Tcw Gp holds 0.76% or 1.33 million shares. Ing Groep Nv owns 20,874 shares for 0.02% of their portfolio. Etrade Cap Limited Liability Company holds 0.02% or 7,261 shares in its portfolio. 16.60M were reported by Vanguard Group. Macguire Cheswick And Tuttle Investment Counsel Limited has invested 1.87% in Pentair plc (NYSE:PNR). Gemmer Asset Management Limited Liability holds 0.01% or 334 shares in its portfolio. Private Wealth Partners Lc reported 0.17% of its portfolio in Pentair plc (NYSE:PNR). Cipher Lp has invested 0.32% of its portfolio in Pentair plc (NYSE:PNR).

Pentair plc (NYSE:PNR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts